JPH11510154A - ベンズイミダゾール化合物 - Google Patents
ベンズイミダゾール化合物Info
- Publication number
- JPH11510154A JPH11510154A JP9507360A JP50736097A JPH11510154A JP H11510154 A JPH11510154 A JP H11510154A JP 9507360 A JP9507360 A JP 9507360A JP 50736097 A JP50736097 A JP 50736097A JP H11510154 A JPH11510154 A JP H11510154A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- benzimidazole
- hydrogen atom
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 47
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 40
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims abstract description 31
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims abstract description 30
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims abstract description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- -1 benzimidazole-4-carboxamide compound Chemical class 0.000 claims abstract description 21
- 229940002612 prodrug Drugs 0.000 claims abstract description 18
- 239000000651 prodrug Substances 0.000 claims abstract description 18
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 16
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 12
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 9
- 125000002252 acyl group Chemical group 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000003112 inhibitor Substances 0.000 claims abstract description 7
- 238000001959 radiotherapy Methods 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000012661 PARP inhibitor Substances 0.000 claims description 22
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- JJDMKDXGNVJWCD-UHFFFAOYSA-N 1h-benzimidazole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1N=CN2 JJDMKDXGNVJWCD-UHFFFAOYSA-N 0.000 claims description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 11
- 150000001408 amides Chemical class 0.000 claims description 11
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 11
- 230000001472 cytotoxic effect Effects 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 231100000433 cytotoxic Toxicity 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 150000003536 tetrazoles Chemical class 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- JCMGIFLIMIXLTP-UHFFFAOYSA-N 2-methyl-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(N)=O)=C2NC(C)=NC2=C1 JCMGIFLIMIXLTP-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 235000021317 phosphate Nutrition 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 108010049290 ADP Ribose Transferases Proteins 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
- KXFVEKRQOAGNIL-UHFFFAOYSA-N 2-(4-methoxyphenyl)-n-methyl-1h-benzimidazole-4-carboxamide Chemical class N1C=2C(C(=O)NC)=CC=CC=2N=C1C1=CC=C(OC)C=C1 KXFVEKRQOAGNIL-UHFFFAOYSA-N 0.000 claims description 3
- VANPTVOCOWCFLO-UHFFFAOYSA-N 2-(trifluoromethyl)-1h-benzimidazole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1NC(C(F)(F)F)=N2 VANPTVOCOWCFLO-UHFFFAOYSA-N 0.000 claims description 3
- OBBJGEVEIULNEO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole-4-carboxamide Chemical compound N=1C=2C(C(=O)N)=CC=CC=2NC=1C1=CC=CC=C1 OBBJGEVEIULNEO-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 108091026813 Poly(ADPribose) Proteins 0.000 claims description 3
- 229910000318 alkali metal phosphate Inorganic materials 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- AFINAILKDBCXMX-PBHICJAKSA-N (2s,3r)-2-amino-3-hydroxy-n-(4-octylphenyl)butanamide Chemical compound CCCCCCCCC1=CC=C(NC(=O)[C@@H](N)[C@@H](C)O)C=C1 AFINAILKDBCXMX-PBHICJAKSA-N 0.000 claims 2
- 229940088679 drug related substance Drugs 0.000 claims 2
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 125000000746 allylic group Chemical group 0.000 claims 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000004020 conductor Substances 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 150000002440 hydroxy compounds Chemical class 0.000 claims 1
- 238000002642 intravenous therapy Methods 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- RKOKDYYBPOKUKF-UHFFFAOYSA-N phosphoric acid;hydrobromide Chemical compound Br.OP(O)(O)=O RKOKDYYBPOKUKF-UHFFFAOYSA-N 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 125000004149 thio group Chemical group *S* 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 4
- 238000006467 substitution reaction Methods 0.000 abstract description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract description 2
- 239000002619 cytotoxin Substances 0.000 abstract description 2
- 101710112752 Cytotoxin Proteins 0.000 abstract 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 abstract 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 38
- 239000007787 solid Substances 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- 239000002904 solvent Substances 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 23
- 238000010561 standard procedure Methods 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- 238000001953 recrystallisation Methods 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 229940064734 aminobenzoate Drugs 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 12
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 229960004964 temozolomide Drugs 0.000 description 12
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 11
- BLJHLOLVEXWHFS-UHFFFAOYSA-N methyl 2,3-diaminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1N BLJHLOLVEXWHFS-UHFFFAOYSA-N 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- JRMAQQQTXDJDNC-UHFFFAOYSA-M 2-ethoxy-2-oxoacetate Chemical compound CCOC(=O)C([O-])=O JRMAQQQTXDJDNC-UHFFFAOYSA-M 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 5
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 5
- 229940048086 sodium pyrophosphate Drugs 0.000 description 5
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 5
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 150000003936 benzamides Chemical group 0.000 description 4
- 150000001556 benzimidazoles Chemical class 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 description 3
- MKRGNKRNZLHINT-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=CC(C(N)=O)=C2N1 MKRGNKRNZLHINT-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- IGLWGHRTQOYFDV-UHFFFAOYSA-N 2-carbamoyl-3-nitrobenzoic acid Chemical compound NC(=O)C1=C(C(O)=O)C=CC=C1[N+]([O-])=O IGLWGHRTQOYFDV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 231100001074 DNA strand break Toxicity 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- HDCLJQZLTMJECA-UHFFFAOYSA-N methyl 2-amino-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1N HDCLJQZLTMJECA-UHFFFAOYSA-N 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- WSTRVLAMLMSFML-UHFFFAOYSA-N 2,2,3-trichlorobutanedioic acid Chemical compound OC(=O)C(Cl)C(Cl)(Cl)C(O)=O WSTRVLAMLMSFML-UHFFFAOYSA-N 0.000 description 2
- LZGYSXDYTDCYCR-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole-4-carboxylic acid Chemical compound N=1C=2C(C(=O)O)=CC=CC=2NC=1C1=CC=CC=C1 LZGYSXDYTDCYCR-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical class NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000005025 clonogenic survival Effects 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 229940043239 cytotoxic antineoplastic drug Drugs 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- SRZIRRABHYIAFR-UHFFFAOYSA-N methyl 2-[3-(trifluoromethyl)phenyl]-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=CC(C(F)(F)F)=C1 SRZIRRABHYIAFR-UHFFFAOYSA-N 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- PFPYHYZFFJJQFD-UHFFFAOYSA-N oxalic anhydride Chemical compound O=C1OC1=O PFPYHYZFFJJQFD-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- KKTUQAYCCLMNOA-UHFFFAOYSA-M 2,3-diaminobenzoate Chemical compound NC1=CC=CC(C([O-])=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-M 0.000 description 1
- MXIUWSYTQJLIKE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1C(Cl)=O MXIUWSYTQJLIKE-UHFFFAOYSA-N 0.000 description 1
- BWXFCEOBQGOLJF-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]-1h-benzimidazole-4-carboxamide Chemical compound N1C=2C(C(=O)N)=CC=CC=2N=C1C1=CC=CC(C(F)(F)F)=C1 BWXFCEOBQGOLJF-UHFFFAOYSA-N 0.000 description 1
- OQWIUGDHBCOOEQ-UHFFFAOYSA-N 2-amino-3-nitrobenzoic acid Chemical compound NC1=C(C(=O)O)C=CC=C1[N+](=O)[O-].NC1=C(C(=O)O)C=CC=C1[N+](=O)[O-] OQWIUGDHBCOOEQ-UHFFFAOYSA-N 0.000 description 1
- JJPIVRWTAGQTPQ-UHFFFAOYSA-N 2-amino-3-nitrobenzoic acid Chemical compound NC1=C(C(O)=O)C=CC=C1[N+]([O-])=O JJPIVRWTAGQTPQ-UHFFFAOYSA-N 0.000 description 1
- LVUZVFVJPPDROZ-UHFFFAOYSA-N 2-methyl-1h-benzimidazole-4-carboxylic acid Chemical compound C1=CC(C(O)=O)=C2NC(C)=NC2=C1 LVUZVFVJPPDROZ-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- ROFZMKDROVBLNY-UHFFFAOYSA-N 4-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)OC2=O ROFZMKDROVBLNY-UHFFFAOYSA-N 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ONWGRYXSLTXUDZ-UHFFFAOYSA-N C1=CC(OC)=CC=C1C1=NC2=C(C(O)=O)C=CC=C2N1 Chemical compound C1=CC(OC)=CC=C1C1=NC2=C(C(O)=O)C=CC=C2N1 ONWGRYXSLTXUDZ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000008158 DNA Ligase ATP Human genes 0.000 description 1
- 108010060248 DNA Ligase ATP Proteins 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100021833 Mesencephalic astrocyte-derived neurotrophic factor Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- CHCFOMQHQIQBLZ-UHFFFAOYSA-N azane;phthalic acid Chemical compound N.N.OC(=O)C1=CC=CC=C1C(O)=O CHCFOMQHQIQBLZ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- JKZWPSHYNAEPAA-UHFFFAOYSA-N cyanocarbamic acid Chemical compound OC(=O)NC#N JKZWPSHYNAEPAA-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-M dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)([O-])OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-M 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229940057975 ethyl citrate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- ALVVOMBQFRXMLU-UHFFFAOYSA-N methyl 2-(3-methoxyphenyl)-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=CC(OC)=C1 ALVVOMBQFRXMLU-UHFFFAOYSA-N 0.000 description 1
- RGHPJRXKVLGWSX-UHFFFAOYSA-N methyl 2-(4-aminophenyl)-1h-benzimidazole-4-carboxylate Chemical compound N=1C=2C(C(=O)OC)=CC=CC=2NC=1C1=CC=C(N)C=C1 RGHPJRXKVLGWSX-UHFFFAOYSA-N 0.000 description 1
- HGDDYLPGUIZRHE-UHFFFAOYSA-N methyl 2-phenyl-1h-benzimidazole-4-carboxylate Chemical compound N1C=2C(C(=O)OC)=CC=CC=2N=C1C1=CC=CC=C1 HGDDYLPGUIZRHE-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000005480 nicotinamides Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 酵素ポリ(ADP−リボース)ポリミラーゼまたはPARP(ADP− リボシル転移酵素またはADPRTとしてもまた知られている)の活性を抑制す るための治療に用いる医薬または獣医薬の製造のために、ここに定義された化合 物の使用で、そのような酵素の抑制効果は治療的処置の要素から構成されており 、前記化合物は活性のPARP酵素の抑制剤を提供し、一般的構造式Iを有する ベンズイミダゾール−4−カルボキシアミドであり、 または製薬上許容できる塩および/またはそれらのプロドラッグの形での使用で あって、構造式Iが下記に特徴づけられる使用; Rは水素原子、アルキル、ヒドロキシアルキル(例えばCH2CH2OH )、アシル(例えば、アセチルまたはベンゾイル)または任意に置換されたアリ ル(例えばフェニル)またはアラルキル(例えば、ベンジルまたはカルボキシベ ンジル)のグループから選ばれ、 そして、 R´は水素原子、アルキル、ヒドロキシアルキル(例えばCH2CH2O H)、アシル(例えば、アセチルまたはベンゾイル)および任意に置換されたア リル(例えばフェニル)またはアラルキル(例えば、ベンジルまたはカルボキシ ベ ンジル)のグループから選ばれる。 2. 化合物の使用であって、その中でそのまたは各々のアルキルグループが 存在し、それがアルコキシまたはその他のグループにおいて、そのものであるか 、またはその一部のいずれも1〜6の炭素原子を含んでいる化合物の使用。 3. 請求項1または請求項2に記載の化合物の使用であって、 その中で下記の構造式IIにより特徴づけられる化合物の使用; R1、R2およびR9は各々独立に、水素原子、ヒドロキシ、アルコキシ 、NO2、N3、NR5R6(R5とR6は各々独立に水素原子、アルキルまたはアル コキシ)、NHCOR3(R3はアルキルまたはアリル)、CO2R4(R4は水素 原子またはアルキル)、アミド(例えばCONH2)、テトラゾール、アルキル 、ヒドロキシアルキル、CW3またはW(Wはハロゲン原子)、そしてCNから 選ばれる。 4. 請求項3に記載の化合物の使用であって、その中でR1が水素原子以外 の他のグループで、4´−位置にあり、同時にR2およびR9はそれぞれ水素原子 である使用。 5. 前項までの請求項のいずれかに記載の化合物の使用であって、 その中でR´は構造式IIIを持つ任意に置換されたフェニルグループ である使用; R7、R8およびR10は各々独立に、水素原子、ヒドロキシ、アルコキ シ、NO2、N3、NR5R6(R5とR6は各々独立に水素原子、アルキルまたはア ルコキシ)、NHCOR3(R3はアルキルまたはアリル)、CO2R4(R4は水 素原子またはアルキル)、アミド(例えばCONH2)、テトラゾール、アルキ ル、ヒドロキシアルキル、CW3またはW(Wはハロゲン原子)、そしてCNか ら選ばれる。 6. 請求項5に記載の化合物の使用であって、その中でR7が水素原子以外 の他のグループで、4´−位置にあり、同時にR8およびR10はそれぞれ水素原 子である使用。 7. 請求項1に記載の化合物の使用であって、その中でRがメチル、エチル 、n−プロピル、i−プロピル、n−ブチル、t−ブチルおよびシクロヘキシル から選ばれる使用。 8. 請求項1に記載の化合物の使用であって、その中でR´が水素原子また はアルキルであり、Rはヒドロキシ、アルコキシ、NO2、N3、NR5R6(R5 とR6は各々独立に水素原子、アルキルまたはアルコキシ)、NHCOR3(R3 はアルキルまたはアリル)、CO2R4(R4は水素原子またはアルキル)、アミ ド(例えばCONH2)、テトラゾール、アルキル、ヒドロキシアルキル、CW3 またはW(Wはハロゲン原子)、そしてCNから選ばれるベンゼン環において、 少なくとも1つの置換基を持つフェニルまたはベンジルである使用。 9. 請求項1に記載の化合物の使用であって、その化合物が下記の1つであ る化合物の使用: (a)2−メチルベンゾイミダゾール−4−カルボキシアミド; (b)ベンゾイミダゾール−4−カルボキシアミド; (c)2−フェニルベンゾイミダゾール−4−カルボキシアミド; (d)2−(4´−メトキシフェニル)ベンゾイミダゾール−4−カルボキシ アミド; (e)2−(4´−トリフルオロメチルフェニル)ベンゾイミダゾール−4− カルボキシアミド; (f)2−(4´−ヒドロキシフェニル)ベンゾイミダゾール−4−カルボキ シアミド; (g)2−トリフルオロメチルベンゾイミダゾール−4−カルボキシアミド; (h)2−(4´−メトキシフェニル)−N−メチルベンゾイミダゾール−4 −カルボキシアミド; (i)2−(4´−ニトロフェニル)ベンゾイミダゾール−4−カルボキシア ミド; (j)2−(4´−シアノフェニル)ベンゾイミダゾール−4−カルボキシア ミド; (k)2−(3´−トリフルオロメチルフェニル)ベンゾイミダゾール−4− カルボキシアミド; (l)2−(3´−メトキシフェニル)ベンゾイミダゾール−4−カルボキシ アミド; (m)2−(4´−メトキシフェニル)−1−N−ベンゾイミダゾール−4− カルボキシアミド; (n)2−(4´−アミノフェニル)ベンゾイミダゾール−4−カルボキシア ミド; (o)2−(2´−トリフルオロメチルフェニル)ベンゾイミダゾール−4− カルボキシアミド; (p)N−カルボキシベンチル−2−(4´−メトキシフェニル)−ベンゾイ ミダゾール−4−カルボキシアミド。 10. 前項までの請求項のいずれかに記載の化合物の使用であって、その中で 化合物がりん酸、カルバメートおよびアミノ酸から選ばれる置換基を持つプロド ラッグの形となっている使用。 11. 請求項10に記載の化合物の使用であって、そのプロドラッグが一般的 構造式Iを持つ化合物のりん酸誘導体である使用。 12. 請求項11に記載の化合物の使用であって、前記の化合物が少なくとも 1つのカルボキシルの置換基を持つ構造式Iの化合物から誘導され、水に可溶な アンモニウムまたはアルカリ金属りん酸塩により与えられるりん酸塩のプロドラ ッグの形となっている使用。 13. 請求項12に記載の化合物の使用であって、その中でりん酸塩のプロド ラッグが誘導される構造式Iの化合物が、りん酸ジベンチルと反応するヒドロキ シ基を有している使用。 14. 活性のある薬剤物質の治療における使用であって、一般的構造式Iを持 つベンズイミダゾール化合物、 またはそれらの製薬上許容できる塩、および/またはプロドラッグの形である薬 剤物質の治療における使用; 構造式Iにおけるそれは、下記のように特徴づけられる; Rは水素原子、アルキル、ヒドロキシアルキル(例えばCH2CH2O H)、アシル(例えば、アセチルまたはベンゾイル)または任意に置換されたア リル(例えばフェニル)またはアラルキル(例えば、ベンジルまたはカルボキシ ベンジル)基から選ばれ、但しRは4´−メタンスルフォニルオキシ −2´− メトキシ−フェニル基で ないことを条件とし、 そして、 R´は水素原子、アルキル、ヒドロキシアルキル(例えばCH2CH2 OH)、アシル(例えば、アセチルまたはベンゾイル)または任意に置換された アリル(例えばフェニル)基から選ばれる。 15. 一般的構造式Iを持つ化合物、 またはそれらの製薬上許容できる塩である化合物; この中で、 Rは水素原子、アルキル、ヒドロキシアルキル(例えばCH2CH2OH )、アシル(例えば、アセチルまたはベンゾイル)または任意に置換されたアリ ル(例えば置換されたフェニル)基、または任意に置換されたアラルキル(例え ばベンジルまたはカルボキシベンジル)基から選ばれ、 そして、 R´は水素原子、アルキル、ヒドロキシアルキル(例えばCH2CH2O H)、アシル(例えば、アセチルまたはベンゾイル)または任意に置換されたア リル(例えばフェニル)基から選ばれ、 但しRは4´−メタンスルフォニルオキシ−2´−メトキシ−フェニル 基でないことを条件とする。 16. 請求項10または請求項11に記載の化合物であって、その中で、その または各々のアルキルグループが存在し、それがアルコキシまたはその他のグル ープにおいて、そのものであるか、またはその一部のいずれも1〜6の炭素原子 を持つ化合物。 17. 請求項14、請求項15あるいは請求項16に記載の化合物であって、 その中で、 Rは構造式IIを持つフェニル基を表す化合物; この中で、R1、R2およびR9は各々独立に、水素原子、ヒドロキシ、 アルコキシ、NO2、N3、NR5R6(R5とR6は各々独立に水素原子、アルキル またはアルコキシ)、NHCOR3(R3はアルキルまたはアリル)、CO2R4( R4は水素原子またはアルキル)、アミド(例えばCONH2)、テトラゾール、 アルキル、ヒドロキシアルキル、CW3またはW(Wはハロゲン原子)、そして CNから選ばれる。 18. 請求項17に記載の化合物であって、その中でR1が水素原子以外の他 のグループで、4´−位置にあり、同時にR2およびR9はそれぞれ水素原子であ る化合物。 19. 請求項14から請求項18までののいずれかに記載の化合物であって、 その中でR´は構造式IIIを持つ任意に置換されたフェニルグループ である化合物; ここに、 R7、R8およびR10は各々独立に、水素原子、ヒドロキシ、アルコキ シ、NO2、N3、NR5R6(R5とR6は各々独立に水素原子、アルキルまたはア ルコキシ)、NHCOR3(R3はアルキルまたはアリル)、CO2R4(R4は水 素原子またはアルキル)、アミド(例えばCONH2)、テトラゾール、アルキ ル、ヒドロキシアルキル、CW3またはW(Wはハロゲン原子)、そしてCNか ら選ばれる。 20. 請求項19に記載の化合物であって、その中でR7が水素原子以外の他 のグループで、4´−位置にあり、同時にR8およびR10はそれぞれ水素原子で ある化合物。 21. 請求項14または請求項15に記載の化合物であって、その中でRがメ チル、エチル、n−プロピル、i−プロピル、n−ブチル、t−ブチルおよびシ クロヘキシルから選ばれた化合物。 22. 請求項14にまたは請求項15に記載の化合物であって、その中でR´ が水素原子またはアルキルであり、Rはヒドロキシ、アルコキシ、NO2、N3、 NR5R6(R5とR6は各々独立に水素原子、アルキルまたはアルコキシ)、NH COR3(R3はアルキルまたはアリル)、CO2R4(R4は水素原子またはアル キル)、アミド(例えばCONH2)、テトラゾール、アルキル、ヒドロキシア ルキル、CW3またはW(Wはハロゲン原子)、そしてCNから選ばれるベンゼ ン環において、少なくとも1つの置換基を持つフェニルまたはベンジル基である 化合物。 23. 請求項14に記載の化合物であって、その化合物が下記の1つである化 合物: (a)2−メチルベンゾイミダゾール−4−カルボキシアミド; (b)ベンゾイミダゾール−4−カルボキシアミド; (c)2−(4´−メトキシフェニル)ベンゾイミダゾール−4−カルボキシ アミド; (d)2−(4´−トリフルオロメチルフェニル)ベンゾイミダゾール−4− カルボキシアミド; (e)2−(4´−ヒドロキシフェニル)ベンゾイミダゾール−4−カルボキ シアミド; (f)2−トリフルオロメチルベンゾイミダゾール−4−カルボキシアミド; (g)2−(4´−メトキシフェニル)−N−メチルベンゾイミダゾール−4 −カルボキシアミド; (h)2−(4´−ニトロフェニル)ベンゾイミダゾール−4−カルボキシア ミド; (i)2−(4´−シアノフェニル)ベンゾイミダゾール−4−カルボキシア ミド; (j)2−(3´−トリフルオロメチルフェニル)ベンゾイミダゾール−4− カルボキシアミド; (k)2−(3´−メトキシフェニル)ベンゾイミダゾール−4−カルボキシ アミド; (l)2−(4´−メトキシフェニル)−1−N−ベンゾイミダゾール−4− カルボキシアミド; (m)2−(4´−アミノフェニル)ベンゾイミダゾール−4−カルボキシア ミド; (n)2−(2´−トリフルオロメチルフェニル)ベンゾイミダゾール−4− カルボキシアミド; (o)N−カルボキシベンチル−2−(4´−メトキシフェニル)−ベンゾイ ミダゾール−4−カルボキシアミド 。 24. 請求項14から請求項23のいずれかに記載の化合物であって、その化 合物が経口あるいは静脈内治療の投与に適し、そしてりん酸、カルバメートおよ び アミノ酸から選ばれた置換基を持つプロドラッグの形となっている化合物。 25. 請求項24に記載の化合物であって、そのプロドラッグの形が一般的構 造式Iを持つ化合物のりん酸誘導体である化合物。 26. 請求項25に記載の化合物であって、前記の化合物が少なくとも1つの カルボキシルの置換基を持つ構造式Iの化合物から誘導され、水に可溶なアンモ ニウムまたはアルカリ金属りん酸塩により与えられるりん酸塩のプロドラッグの 形となっている化合物。 27. 請求項26に記載の化合物であって、その中でりん酸塩のプロドラッグ が誘導される構造式Iの化合物が、りん酸ジベンチルと反応するヒドロキシ基を 有している化合物。 28. 請求項17記載の化合物を調整する方法であって、アルキル 2,3− ジアミノベンゾエートが塩化アリル酸と反応し、その生成物を高温でさく酸によ り処理してベンズイミダゾール環を得、アンモニア水との反応でそのアミドの誘 導体を造り出すステップから構成される方法。 29. 活性なPARP−抑制物質として治療のために使用する請求項14から 請求項27のいずれかに記載の化合物。 30. 哺乳動物の治療処置に用いるための医学あるいは獣医学の薬剤の製造の ための、請求項14から請求項27のいずれかに記載の化合物の使用。 31. 治療中にPARP−抑制剤で処置を施すことから恩恵を受ける哺乳動物 に投薬するために仕上げられる単位服用薬において、請求項29に記載の化合物 を含む薬剤の処方あるいは組成。 32. 薬剤的に許容できる担持体を伴った請求項14から請求項27のいずれ かに記載の化合物の有効なPARP−抑制の量を有している薬剤使用のための製 薬上の処方あるいは組成。 33. 抗腫瘍の治療において、細胞毒性剤あるいは放射線治療と組み合わせて 使用するための、請求項31または請求項32に記載の製薬的処方あるいは組成 。 34. 抗腫瘍による治療に使用のため、治療として有用でかつ効果的な量を混 入する場合に、請求項29に記載の化合物の有効なPARP−抑制の量を有して いる製薬上の組成。 35. 哺乳動物に施される治療処置の方法であって、そこでPARP酵素の活 性の禁止による恩恵を受けやすい、前記の哺乳動物に請求項14から請求項27 のいずれかに記載の化合物の効果的なPARP−抑制の量を投与することから成 る、前記の治療処置の方法。 36. 抗腫瘍の治療中に、DNAを破壊する細胞毒性ドラッグの投与、あるい は抗腫瘍の治療中の放射線照射と組み合わせて実施する請求項35に記載の治療 処置の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9515843.2A GB9515843D0 (en) | 1995-08-02 | 1995-08-02 | Benzimidazole compounds |
GB9515843.2 | 1995-08-02 | ||
GBGB9611245.3A GB9611245D0 (en) | 1996-05-30 | 1996-05-30 | Benzimidazole compounds |
GB9611245.3 | 1996-05-30 | ||
PCT/GB1996/001832 WO1997004771A1 (en) | 1995-08-02 | 1996-07-30 | Benzimidazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11510154A true JPH11510154A (ja) | 1999-09-07 |
Family
ID=26307504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9507360A Ceased JPH11510154A (ja) | 1995-08-02 | 1996-07-30 | ベンズイミダゾール化合物 |
Country Status (26)
Country | Link |
---|---|
US (2) | US6100283A (ja) |
EP (1) | EP0841924B1 (ja) |
JP (1) | JPH11510154A (ja) |
KR (1) | KR100447539B1 (ja) |
CN (1) | CN1159007C (ja) |
AP (1) | AP866A (ja) |
AT (1) | ATE225173T1 (ja) |
AU (1) | AU714873B2 (ja) |
BR (1) | BR9610051A (ja) |
CA (1) | CA2225465A1 (ja) |
CZ (1) | CZ30398A3 (ja) |
DE (1) | DE69624115T2 (ja) |
DK (1) | DK0841924T3 (ja) |
EA (1) | EA000999B1 (ja) |
ES (1) | ES2183004T3 (ja) |
HU (1) | HUP9901092A3 (ja) |
IL (1) | IL123147A (ja) |
MX (1) | MX9800927A (ja) |
NO (1) | NO317033B1 (ja) |
NZ (1) | NZ313713A (ja) |
OA (1) | OA10661A (ja) |
PL (1) | PL324869A1 (ja) |
PT (1) | PT841924E (ja) |
SK (1) | SK13598A3 (ja) |
TR (1) | TR199800127T1 (ja) |
WO (1) | WO1997004771A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523801A (ja) * | 2006-01-17 | 2009-06-25 | アボット・ラボラトリーズ | Parpインヒビターとの組合せ療法 |
JP2013521255A (ja) * | 2010-03-04 | 2013-06-10 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | フルオロアルキル置換2−アミドベンズイミダゾールおよび植物中のストレス耐性を強化するためのその使用 |
JP2021510173A (ja) * | 2018-01-05 | 2021-04-15 | サイブレクサ 1・インコーポレイテッドCybrexa 1, Inc. | 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法 |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2776291B1 (fr) * | 1998-03-18 | 2000-06-16 | Pf Medicament | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament |
US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
UA65635C2 (uk) | 1998-09-03 | 2004-04-15 | Н-Гене Кутато Кфт. | НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ |
DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
SK6742001A3 (en) * | 1998-11-17 | 2001-12-03 | Basf Ag | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
PT1133477E (pt) | 1998-11-27 | 2004-06-30 | Abbott Gmbh & Co Kg | Benzimidazois substituidos e a utilizacao dos mesmos como inibidores da parp |
DE19916460B4 (de) * | 1999-04-12 | 2006-12-21 | Abbott Gmbh & Co. Kg | Substituierte Benzimidazole, deren Herstellung und Anwendung |
EP1140936B1 (en) * | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
FR2788518B1 (fr) * | 1999-01-14 | 2001-03-02 | Centre Nat Rech Scient | Nouveaux carbamates actives stables, leur procede de preparation et leur utilisation pour la preparation d'urees |
DE19918211A1 (de) * | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
WO2001021615A1 (en) * | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
DE19946289A1 (de) * | 1999-09-28 | 2001-03-29 | Basf Ag | Benzodiazepin-Derivate, deren Herstellung und Anwendung |
US6759425B2 (en) | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
IT1315267B1 (it) * | 1999-12-23 | 2003-02-03 | Novuspharma Spa | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale |
ES2290115T3 (es) | 2000-02-01 | 2008-02-16 | ABBOTT GMBH & CO. KG | Compuestos heterociclicos y su aplicacion como inhibidores de parp. |
DE10021468A1 (de) * | 2000-05-04 | 2001-11-08 | Basf Ag | Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen |
DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
RU2003127367A (ru) * | 2001-03-12 | 2005-03-20 | Аванир Фармасьютиклз (Us) | Бензимидазоловые соединения для модулирования ige и ингибирования клеточной пролиферации |
US7072771B2 (en) * | 2001-06-07 | 2006-07-04 | University Of Kentucky Research Foundation | Selective PARP-1 targeting for designing chemo/radio sensitizing agents |
WO2003020698A2 (en) * | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
DE10201240A1 (de) * | 2002-01-15 | 2003-07-24 | Bayer Ag | Substituierte Alkyluracile und ihre Verwendung |
TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
US20040034078A1 (en) * | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
WO2004065370A1 (en) * | 2003-01-23 | 2004-08-05 | Crystalgenomics, Inc. | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof |
US7132440B2 (en) * | 2003-04-17 | 2006-11-07 | Janssen Pharmaceutica, N.V. | Substituted benzimidazoles and imidazo-[4,5]-pyridines |
CA2533990A1 (en) * | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
NZ565654A (en) | 2005-07-18 | 2010-10-29 | Bipar Sciences Inc | Use of iodonitrobenzamide compounds for the treatment of ovarian cancer |
ATE540689T1 (de) | 2005-11-14 | 2012-01-15 | Centre Nat Rech Scient | Macroh2a non-histone domäne als hemmer der parp-1-aktivität und verwendung davon |
ATE461923T1 (de) | 2005-11-15 | 2010-04-15 | Abbott Lab | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
US20090029966A1 (en) * | 2006-01-17 | 2009-01-29 | Abbott Laboratories | Combination therapy with parp inhibitors |
US20080146638A1 (en) * | 2006-01-17 | 2008-06-19 | Abbott Laboratories | Combination therapy with parp inhibitors |
US20080293795A1 (en) * | 2006-01-17 | 2008-11-27 | Abbott Laboratories | Combination therapy with parp inhibitors |
US20080280867A1 (en) * | 2006-01-17 | 2008-11-13 | Abbott Laboratories | Combination therapy with parp inhibitors |
JP4611441B2 (ja) * | 2006-04-03 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
ES2385849T3 (es) | 2006-05-02 | 2012-08-01 | Abbott Laboratories | Las 1H-bencimidazol-4-carboxamidas substituidas son potentes inhibidores de la PARP |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
EP2061479A4 (en) | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH |
AU2007292302A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing PARP inhibitors and uses thereof |
CN101522609A (zh) | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
WO2008084261A1 (en) | 2007-01-10 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
US20090062268A1 (en) * | 2007-08-27 | 2009-03-05 | Lead Therapeutics, Inc. | Novel inhibitors of poly(adp-ribose)polymerase (parp) |
JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ,インコーポレイティド | ベンゾピロン系parp阻害剤を用いる癌の処置方法および組成物 |
JP2011503111A (ja) | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ,インコーポレイティド | Parp阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
US8436185B2 (en) | 2008-01-08 | 2013-05-07 | Merck Sharp & Dohme Corp. | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
RU2010136966A (ru) * | 2008-02-04 | 2012-03-20 | Байпар Сайенсиз, Инк. (Us) | Способы диагностики и лечения заболеваний, опосредованных parp |
WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
CN102417483A (zh) * | 2010-09-27 | 2012-04-18 | 中国药科大学 | 作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物 |
EP2561759A1 (en) | 2011-08-26 | 2013-02-27 | Bayer Cropscience AG | Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth |
CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
CN102627610B (zh) * | 2012-04-11 | 2014-06-25 | 江苏先声药物研究有限公司 | 一类苯并咪唑类衍生物及其应用 |
US20150216168A1 (en) * | 2012-09-05 | 2015-08-06 | Bayer Cropscience Ag | Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress |
CN104140426B (zh) * | 2013-05-07 | 2017-02-01 | 上海汇伦生命科技有限公司 | 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途 |
CN104230896A (zh) * | 2013-06-17 | 2014-12-24 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
CN107556288A (zh) * | 2016-07-01 | 2018-01-09 | 山东大学齐鲁医院 | 一种治疗转移性肿瘤的药物化合物 |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
CN110300600A (zh) | 2016-11-02 | 2019-10-01 | 伊缪诺金公司 | 利用抗体-药物缀合物和parp抑制剂的组合治疗 |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
CA3146385A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
CN111793034B (zh) * | 2020-07-24 | 2021-11-19 | 华中科技大学 | 苯并咪唑盐衍生物与制备抗肿瘤药物的应用 |
MX2023008146A (es) | 2021-01-08 | 2023-07-24 | Cybrexa 2 Inc | Proceso para preparar un resto enlazador de conjugados. |
WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1087561A (en) * | 1963-02-16 | 1967-10-18 | Fisons Pest Control Ltd | Fluorinated benzimidazoles and compositions containing them |
DE3346575A1 (de) * | 1983-12-23 | 1985-07-04 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel |
DE3522230A1 (de) * | 1985-06-21 | 1987-01-02 | Thomae Gmbh Dr K | Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
GB8822483D0 (en) * | 1988-09-24 | 1988-10-26 | Medical Res Council | Developments relating to mas oncogene |
GB8904174D0 (en) * | 1989-02-23 | 1989-04-05 | British Bio Technology | Compounds |
IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
IL95975A (en) * | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
WO1992005784A1 (en) * | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
US5216003A (en) * | 1992-01-02 | 1993-06-01 | G. D. Searle & Co. | Diacid-containing benzimidazole compounds for treatment of neurotoxic injury |
AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
US5735973A (en) * | 1993-12-20 | 1998-04-07 | Tamura Kaken Corporation | Printed circuit board surface protective agent |
US5821258A (en) * | 1994-12-27 | 1998-10-13 | Mitsui Chemicals, Inc. | Phenylbenzimidazole derivatives |
-
1996
- 1996-07-30 ES ES96925875T patent/ES2183004T3/es not_active Expired - Lifetime
- 1996-07-30 PL PL96324869A patent/PL324869A1/xx unknown
- 1996-07-30 DK DK96925875T patent/DK0841924T3/da active
- 1996-07-30 AP APAP/P/1998/001183A patent/AP866A/en active
- 1996-07-30 EP EP96925875A patent/EP0841924B1/en not_active Expired - Lifetime
- 1996-07-30 EA EA199800184A patent/EA000999B1/ru not_active IP Right Cessation
- 1996-07-30 JP JP9507360A patent/JPH11510154A/ja not_active Ceased
- 1996-07-30 IL IL12314796A patent/IL123147A/en not_active IP Right Cessation
- 1996-07-30 BR BR9610051-6A patent/BR9610051A/pt not_active Application Discontinuation
- 1996-07-30 AU AU66240/96A patent/AU714873B2/en not_active Ceased
- 1996-07-30 SK SK135-98A patent/SK13598A3/sk unknown
- 1996-07-30 CA CA002225465A patent/CA2225465A1/en not_active Abandoned
- 1996-07-30 DE DE69624115T patent/DE69624115T2/de not_active Expired - Fee Related
- 1996-07-30 WO PCT/GB1996/001832 patent/WO1997004771A1/en not_active Application Discontinuation
- 1996-07-30 KR KR10-1998-0700752A patent/KR100447539B1/ko not_active IP Right Cessation
- 1996-07-30 TR TR1998/00127T patent/TR199800127T1/xx unknown
- 1996-07-30 AT AT96925875T patent/ATE225173T1/de not_active IP Right Cessation
- 1996-07-30 CZ CZ98303A patent/CZ30398A3/cs unknown
- 1996-07-30 NZ NZ313713A patent/NZ313713A/en unknown
- 1996-07-30 PT PT96925875T patent/PT841924E/pt unknown
- 1996-07-30 HU HU9901092A patent/HUP9901092A3/hu not_active Application Discontinuation
- 1996-07-31 CN CNB961968818A patent/CN1159007C/zh not_active Expired - Fee Related
-
1998
- 1998-01-30 OA OA9800017A patent/OA10661A/en unknown
- 1998-01-30 NO NO19980414A patent/NO317033B1/no not_active IP Right Cessation
- 1998-02-02 US US09/017,314 patent/US6100283A/en not_active Expired - Fee Related
- 1998-02-02 MX MX9800927A patent/MX9800927A/es not_active IP Right Cessation
-
2000
- 2000-06-16 US US09/594,776 patent/US6310082B1/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523801A (ja) * | 2006-01-17 | 2009-06-25 | アボット・ラボラトリーズ | Parpインヒビターとの組合せ療法 |
JP2017160216A (ja) * | 2006-01-17 | 2017-09-14 | アッヴィ・アイルランド・アンリミテッド・カンパニー | Parpインヒビターとの組合せ療法 |
JP2013521255A (ja) * | 2010-03-04 | 2013-06-10 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | フルオロアルキル置換2−アミドベンズイミダゾールおよび植物中のストレス耐性を強化するためのその使用 |
JP2021510173A (ja) * | 2018-01-05 | 2021-04-15 | サイブレクサ 1・インコーポレイテッドCybrexa 1, Inc. | 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11510154A (ja) | ベンズイミダゾール化合物 | |
JPH09510704A (ja) | Parp(adp−リボシルトランスフェラーゼ、adprt)および修復酵素として有用なベンズアミド類似体 | |
JPS5980666A (ja) | ベンズイミダゾ−ル類 | |
JPH05366B2 (ja) | ||
JP2016511237A (ja) | 選択的hdac3阻害剤 | |
EP2238110B1 (fr) | Dérivés de 5.6-bisaryl-2-pyr1dine-carboxamide, leur préparatio leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii | |
JP2003525936A (ja) | Rafキナーゼ阻害物質としてのイミダゾール誘導体 | |
JP2002540207A (ja) | ピリミド[6,1−a]イソキノリン−4−オン誘導体 | |
CN108524482A (zh) | 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途 | |
JP2010513402A (ja) | ステアロイル−CoAデサチュラーゼ(SCD)阻害薬としてのイソキノリンカルボキサミド誘導体 | |
CN107163044A (zh) | 一类具有蛋白酶修饰活性的萘乙二酮化合物及其衍生物 | |
RU2282627C2 (ru) | Кумариновые производные с подавляющей комт активностью | |
EP3515904B1 (en) | Benzoimidazole derivatives as anticancer agents | |
CN115947716B (zh) | 一种靶向Nur77的吲哚衍生物及其应用 | |
CN117069696B (zh) | 一种双靶点小分子抑制剂及其制备方法和应用 | |
TW202317586A (zh) | 治療性化合物及方法 | |
CN115819349A (zh) | 一种吡唑类化合物及其制备方法和应用 | |
JPH02255664A (ja) | 7―オキソシクロペンタ〔d〕ピリミジン誘導体 | |
CA2350941A1 (en) | Benzamide analogues as parp dna repair enzyme inhibitors | |
JPH10316649A (ja) | ナフタレンスルホンアミド誘導体及びこれを含有する医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041019 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041007 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20050314 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050419 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060926 |